Business Context and Reporting Period
NanoViricides, Inc. (Nevada corporation) filed this Form 8-K on January 7, 2015, reporting events occurring on December 31, 2014. The company is a biotechnology firm focused on developing antiviral therapies.
Key Financial Metrics and Transaction Details
This filing reports a specific asset acquisition rather than periodic financial performance. Key transaction figures include:
- Purchase Price: $4,300,938.76 total (comprised of $4,222,458.54 for acquisition/renovation costs and $77,480.22 for closing costs).
- Asset Acquired: An 18,000 square foot cGMP-compliant pilot manufacturing and lab facility on approximately 4.2 acres in Shelton, Connecticut.
- Additional Direct Costs: $5,145,329.71 paid by the Registrant for design, engineering, equipment, and fixtures (previously reported, not part of the purchase price).
- Counterparty: Inno-Haven, LLC.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Related Party Disclosure
The primary material change is the entry into a definitive agreement to acquire the manufacturing facility. This transaction involves a related party:
- Anil Diwan, PhD, the Registrant's founder, President, and Chairman, is the sole member and manager of the seller, Inno-Haven, LLC.
- Dr. Diwan abstained from participating in any capacity on the transaction on behalf of the Registrant.
- The purchase price was structured as a repayment of the seller's direct costs incurred in acquiring and renovating the property.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the inherent nature of the related-party transaction. The acquisition supports the company's need for a cGMP-compliant facility for specialized use.
Investor Verification Checklist
- Verify the valuation of the facility against the "cost-plus" purchase price structure.
- Confirm the total capital outlay including the $5.1M in additional direct costs previously reported.
- Review the related party transaction disclosure to ensure compliance with governance standards regarding Dr. Diwan's abstention.
- Assess the impact of this capital expenditure on the company's current cash position and liquidity.